Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-2723
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans ; volume:43 ; number:5 ; day:11 ; month:10 ; year:2021 ; pages:2321-2331 ; date:10.2021
GeroScience ; 43, Heft 5 (11.10.2021), 2321-2331, 10.2021
- Urheber
-
Vályi-Nagy, István
Matula, Zsolt
Gönczi, Márton
Tasnády, Szabolcs
Bekő, Gabriella
Réti, Marienn
Ajzner, Éva
Uher, Ferenc
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11357-021-00471-6
- URN
-
urn:nbn:de:101:1-2022012719222658344797
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:27 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vályi-Nagy, István
- Matula, Zsolt
- Gönczi, Márton
- Tasnády, Szabolcs
- Bekő, Gabriella
- Réti, Marienn
- Ajzner, Éva
- Uher, Ferenc
- SpringerLink (Online service)
Ähnliche Objekte (12)
Longitudinal study of antibody response following SARS-CoV-2 vaccination with Pfizer-BioNTech BNT162b2
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
P04-21. Different human serum antibody profiles elicited by three candidate HIV vaccines using different immunization approaches
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Pfizer
Advances in antibody-based HIV-1 vaccines development
Longitudinal study of antibody response following SARS-CoV-2 vaccination with Pfizer-BioNTech BNT162b2
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
P04-21. Different human serum antibody profiles elicited by three candidate HIV vaccines using different immunization approaches
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Pfizer
Advances in antibody-based HIV-1 vaccines development
Longitudinal study of antibody response following SARS-CoV-2 vaccination with Pfizer-BioNTech BNT162b2
Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
P04-21. Different human serum antibody profiles elicited by three candidate HIV vaccines using different immunization approaches
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Pfizer